Does CBD have side effects?

Yes, but they are rare and benign. The most common: drowsiness at high dose (5-10 %), mild dry mouth (3-5 %), transient digestive issues (1-3 %). Safety profile recognised by the WHO as "excellent" in 2018.

Can CBD damage the liver?

At therapeutic dose ( 600 mg/day): moderate and reversible elevation of transaminases in some patients. FDA 2018 study on Epidyolex (CBD at 10-20 mg/kg dose). Hepatic panel recommended if high dose > 3 months.

Can CBD cause anxiety instead of calming it?

Very rare and paradoxical. Can happen in some sensitive profiles, particularly at high dose (> 400 mg acute). CBD being biphasic, exceeding the optimal dose can reverse the anxiolytic effect into a moderate anxiogenic one.

Does CBD interact with my medications?

Yes, potentially. CBD inhibits CYP3A4 and CYP2C19 (hepatic enzymes). It may increase concentrations of: warfarin, phenytoin, clobazam, cyclosporine, some antidepressants. Always consult your doctor if on chronic treatment.

Can you become dependent on CBD?

No. The WHO in its 2018 report explicitly stated: "CBD shows no potential for abuse and is not likely to pose a public health concern." No withdrawal syndrome documented at cessation.

CBD Side Effects and Safety Profile (Complete Review)

Name: WorldWeed
Price range: €€

CBD has the reputation of being "side-effect free". That's an oversimplification. The reality: CBD has an exceptional safety profile for an active molecule, but like any pharmacological substance, it can cause adverse effects. Here's the complete list, by frequency and dose-dependence.

Overview: what the WHO says

In its 2018 critical review report (ECDD, 40th session), the World Health Organisation concluded:

"CBD is generally well tolerated with a good safety profile. Adverse effects reported may be due to drug-drug interactions between CBD and other medications. CBD does not appear to have abuse potential or to cause dependence."

This is one of the most favourable opinions the WHO has ever given on an active substance.

Common side effects (1-10 % of users)

😴 Drowsiness

Frequency: 5-10 % at moderate dose, more at high dose
Dose-dependent: yes (> 50 mg per intake = frequent drowsiness)
Management: take in the evening, reduce dose, don't drive within 4h

🌵 Dry mouth (xerostomia)

Frequency: 3-5 %
Mechanism: CB1 receptors in salivary glands
Management: hydrate well, the effect decreases with regular use

💩 Digestive issues

Frequency: 1-3 %
Symptoms: diarrhoea, mild nausea, bloating
Possible cause: intolerance to the carrier oil (MCT, sometimes poorly digested)
Management: change oil brand, take with a meal

🍽️ Appetite modification

Frequency: 5-8 %
Direction: variable — some increase appetite, others decrease it
Management: monitor weight, adjust dose

Less frequent side effects (<1 %)

🤕 Headaches

Frequency: ~1 %
Often: at very high dose or beginning of use
Management: hydration, reduce dose

😵 Dizziness / floating sensation

Frequency: <1 %
Cause: mild vasodilator effect of CBD, moderate blood pressure drop
Management: stand up slowly, especially at beginning of use

🩸 Mild hypotension

Frequency: <1 %, especially at high doses
At-risk population: people already on antihypertensives
Management: blood pressure monitoring if hypertension treatment

Rare and dose-dependent effects

🧬 Elevated hepatic transaminases

This is the only serious effect to know. At high therapeutic dose (> 600 mg/day for > 1 month), 5-15 % of patients show moderate and reversible elevation of ALT (alanine aminotransferase).

Source: FDA 2018 study on Epidyolex (CBD for paediatric epilepsy at 10-20 mg/kg/day).

Recommendation:

At normal dose (< 100 mg/day): no demonstrated risk
If dose > 200 mg/day for > 3 months: hepatic panel recommended
If existing hepatic pathology: medical advice before any use

🩸 Modifications of drug blood levels

Linked to enzymatic interactions (see dedicated section below).

Drug interactions

CBD inhibits two major hepatic enzymes:

CYP3A4: metabolises about 50 % of medications
CYP2C19: metabolises antidepressants, PPIs, some antiepileptics

Medications with notable interaction risk

| Medication | Risk | Recommendation | |---|---|---| | Warfarin, AVK | Increased blood level → bleeding | Medical advice + INR monitoring | | Phenytoin, phenobarbital | Concentration modification | Dose monitoring | | Clobazam | Marked increase in active metabolite | Reduce clobazam dose | | Cyclosporine | Increased level | Monitor level + creatinine | | Tacrolimus | Possible increase | Monitor blood level | | Paroxetine, fluoxetine | Additive effect | Psychiatrist advice | | Atorvastatin, simvastatin | Possible increase | Monitor CPK | | Macrolides (clarithromycin) | Additive CYP3A4 effect | Space intakes |

Medications WITHOUT notable interaction

Paracetamol, ibuprofen
Antacids (omeprazole)
Vitamins, minerals
Basic antibiotics (amoxicillin, except macrolides)
Modern antihistamines (cetirizine, loratadine)

Paradoxical effects

Anxiety or irritability

Rare (<1 %) but documented. Occurs mostly at high dose (> 300 mg acute) or in sensitive profiles (young, psychiatric history).

Linked to the bell curve: beyond the optimal dose, the anxiolytic effect may reverse.

If it happens: significantly reduce dose, take a break for a few days, then resume at lower dose.

Safety profile by population

Healthy adults

Excellent. Very wide therapeutic margin. No documented mortality from CBD in the literature.

Elderly

Good, with dose adjustment. Slowed hepatic metabolism → start at 50 % adult dose.

Pregnant or breastfeeding women

Avoid by precautionary principle. Insufficient human data. CBD crosses the placental barrier in animals.

Children

Framework only. Paediatric CBD (Epidyolex for severe epilepsy) is reserved for specialist prescription.

People on chronic treatment

Medical advice mandatory before any use, especially for:

Anticoagulants
Antiepileptics
Immunosuppressants
Antidepressants
Drugs with narrow therapeutic window

What to do if you experience an adverse effect?

Mild effect (drowsiness, dry mouth): adjust dose or intake timing.
Moderate effect (digestive issues > 48h): stop, wait 48h, resume at lower dose.
Severe effect (repeated vomiting, malaise, jaundice): stop immediately, consult.
Always report to pharmacist if drug interaction suspected.

Comparison with other substances

| Substance | Typical toxic dose | Dependence risk | Major side effects | |---|---|---|---| | CBD | > 1500 mg/day | None | Drowsiness, transaminases | | Paracetamol | > 4 g/day | None | Lethal hepatitis above | | Ibuprofen | > 3 g/day | None | Ulcer, renal failure | | Alcohol | Variable | Strong | Cirrhosis, lethal withdrawal | | Benzodiazepines | Variable | Strong | Severe withdrawal, sedation | | Caffeine | > 1 g/day | Moderate | Tachycardia, anxiety |

CBD has a higher safety profile than most over-the-counter pain relievers. This is one of its strongest arguments.

Conclusion: what to remember?

✅ CBD has an excellent safety profile validated by WHO, FDA, ANSM ✅ Rare and benign side effects (drowsiness, dry mouth mainly) ✅ No addictive potential, no withdrawal at cessation ⚠️ Drug interactions to monitor (CYP3A4, CYP2C19) ⚠️ Avoid during pregnancy / breastfeeding ⚠️ Medical advice if chronic treatment or hepatic pathology

Scientific sources

World Health Organization. Cannabidiol (CBD) Critical Review Report. ECDD 40th session, 2018.
Iffland K, Grotenhermen F. "An update on safety and side effects of cannabidiol..." Cannabis Cannabinoid Res. 2017.
Brown JD, Winterstein AG. "Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use" J Clin Med. 2019.
FDA. Briefing document on Epidiolex (cannabidiol). 2018.
Larsen C, Shahinas J. "Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review..." J Clin Med Res. 2020.